HUTCHMED (China) マネジメント

マネジメント基準チェック /44

HUTCHMED (China)の CEO はWei-Guo Suで、 Jan2012年に任命され、の在任期間は 12.83年です。の年間総報酬は$ 2.45Mで、 32.5%給与と67.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.49%を直接所有しており、その価値は£ 11.64M 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と7.7年です。

主要情報

Wei-Guo Su

最高経営責任者

US$2.5m

報酬総額

CEO給与比率	32.5%
CEO在任期間	12.8yrs
CEOの所有権	0.5%
経営陣の平均在職期間	6.5yrs
取締役会の平均在任期間	7.7yrs

経営陣の近況

Recent updates

HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

Oct 19

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Sep 10

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Jul 11

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

CEO報酬分析

HUTCHMED (China) の収益と比較して、Wei-Guo Su の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$42m
Mar 31 2024	n/a	n/a	US$29m
Dec 31 2023	US$2m	US$798k	US$101m
Sep 30 2023	n/a	n/a	US$36m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$195m
Dec 31 2022	US$4m	US$700k	-US$361m
Sep 30 2022	n/a	n/a	-US$308m
Jun 30 2022	n/a	n/a	-US$255m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$3m	US$395k	-US$195m
Sep 30 2021	n/a	n/a	-US$187m
Jun 30 2021	n/a	n/a	-US$178m
Mar 31 2021	n/a	n/a	-US$151m
Dec 31 2020	US$1m	US$346k	-US$126m
Sep 30 2020	n/a	n/a	-US$117m
Jun 30 2020	n/a	n/a	-US$110m
Mar 31 2020	n/a	n/a	-US$102m
Dec 31 2019	US$1m	US$274k	-US$106m
Sep 30 2019	n/a	n/a	-US$93m
Jun 30 2019	n/a	n/a	-US$87m
Mar 31 2019	n/a	n/a	-US$83m
Dec 31 2018	US$1m	US$273k	-US$75m
Sep 30 2018	n/a	n/a	-US$72m
Jun 30 2018	n/a	n/a	-US$61m
Mar 31 2018	n/a	n/a	-US$39m
Dec 31 2017	US$2m	US$310k	-US$27m

報酬と市場: Wei-Guoの総報酬 ($USD 2.45M ) は、 UK市場 ($USD 2.68M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Wei-Guoの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Wei-Guo Su (66 yo)

12.8yrs

在職期間

US$2,451,164

報酬

Dr. Wei-Guo Su, B.Sc., Ph D., has been the Chief Executive Officer of HUTCHMED (China) Limited since March 04, 2022. Dr. Su has been the Chief Scientific Officer and Executive Vice President of HUTCHMED (C...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Wei-Guo Su	CEO, Chief Scientific Officer & Executive Director	12.8yrs	US$2.45m	0.49% £ 11.6m
Chig Fung Cheng	CFO & Executive Director	16.3yrs	US$962.15k	0.18% £ 4.3m
Edith Shih	Company Secretary & Non-Executive Director	18.8yrs	データなし	データなし
Yiling Cui	Executive VP & Head of Operations	less than a year	データなし	データなし
David Ng	Head of Investor Relations & Capital Strategies	no data	データなし	データなし
Charles George Rupert Nixon	Group General Counsel	9.5yrs	データなし	データなし
Kin Hung Lee	Senior Vice President of Corporate Management & Communications	1.8yrs	データなし	データなし
Selina Zhang	Senior Vice President of Global Human Resources	2.8yrs	データなし	データなし
Qingmei Wang	Senior Vice President of Business Development & Strategic Alliances	no data	データなし	データなし
Zhenping Wu	Executive Vice President of Pharmaceutical Science & Manufacturing	12.8yrs	データなし	データなし
Thomas Fu	Senior Vice President of Global Quality	3.6yrs	データなし	データなし
Ming Shi	Executive VP	2.3yrs	データなし	データなし

6.5yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: HCMの経営陣は経験豊富で経験豊富です（平均在職期間は6.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Wei-Guo Su	CEO, Chief Scientific Officer & Executive Director	7.7yrs	US$2.45m	0.49% £ 11.6m
Chig Fung Cheng	CFO & Executive Director	13.8yrs	US$962.15k	0.18% £ 4.3m
Edith Shih	Company Secretary & Non-Executive Director	18.8yrs	データなし	データなし
Dan Eldar	Non-Executive Chairman	8.3yrs	データなし	0.013% £ 304.6k
Ling Yang	Non-Executive Director	1.3yrs	データなし	データなし
Graeme Allan Jack	Independent Non-Executive Director	7.7yrs	US$111.00k	0.0053% £ 126.9k
Paul Rutherford Carter	Senior Independent Non-Executive Director	7.8yrs	US$117.00k	0.0087% £ 205.8k
Shu Kam Mok	Independent Non-Executive Director	7.1yrs	US$114.86k	0.011% £ 265.9k
Renu Bhatia	Independent Non-Executive Director	less than a year	データなし	データなし

7.7yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: HCMの取締役会は経験豊富であると考えられます ( 7.7年の平均在任期間)。

HUTCHMED (China) マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

Key Executive exercised options to buy UK£6.7m worth of stock.

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Recent updates

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Investor sentiment improves as stock rises 16%

Consensus EPS estimates upgraded to US$0.11 loss

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Consensus EPS estimates upgraded to US$0.25 loss

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

マネジメント基準チェック /44